$2.3bn deal brings nitric oxide ventilator system for newborns with respiratory failure

Specialist pharmaceutical firm Mallinckrodt has agreed to buy critical care firm Ikaria for $2.3 billion (£1.5 billion). The deal expands Mallinckrodt’s presence in US hospitals beyond diagnostics and surgical pain management and into intensive care.

Mallinckrodt will gain access to Ikaria’s inhaled nitric oxide (iNO) delivery system, which is used to treat newborn babies with respiratory failure. The devices are compatible with hospital ventilator systems and deliver regulated doses of NO to dilate blood vessels and improve blood oxygenation.